Please use this identifier to cite or link to this item:
http://repositorio.unitau.br/jspui/handle/20.500.11874/2985
metadata.dc.type: | Artigo de Periódico |
Title: | Clinical and Microbiologic Evaluation of Scaling and Root Planing per Quadrant and One-Stage Full-Mouth Disinfection Associated With Azithromycin or Chlorhexidine: A Clinical Randomized Controlled Trial |
Authors: | Fonseca, Douglas Campideli Cortelli, José Roberto Cortelli, Sheila Cavalca Cota, Luís Otávio de Miranda Costa, Lidiane Cristina Machado Castro, Marcos Vinicius Moreira Azevedo, Andrea Mara Oliveira Costa, Fernando Oliveira |
Abstract: | Background: Conflicting data about the protocol of choice for non-psurgical periodontal therapy with adjuvant use are still reported. This study aims to evaluate, through clinical and microbiologic parameters, the systemic use of azithromycin (AZ) and chlorhexidine (CHX) as adjuvants to non-psurgical periodontal treatment performed by one-pstage full-pmouth disinfection (FMD) within 24 hours or conventional quadrant scaling (QS) in four weekly sections. Methods: In this randomized controlled trial, 85 patients diagnosed with chronic periodontitis underwent different treatment protocols, in six groups: three FMD groups and three QS groups, each with no adjuvants, with CHX, and with AZ. Clinical periodontal parameters were recorded, and total and quantitative bacterial counts of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, and Streptococcus oralis were measured with real-ptime polymerase chain reaction at baseline and 90 and 180 days after treatment. Results: In all groups, a significant reduction was observed in the percentage of periodontal diseased sites, gingival index, plaque index, and clinical attachment level gain at 90 days, demonstrating effectiveness of the treatment, independently of the adjuvant. The FMD with CHX group showed higher reduction in probing depth and percentage of periodontal diseases sites, as well as lower total bacterial count, than all the other groups at 180 days. Conclusions: The adjuvant use of AZ did not provide any significant benefit, independently of the treatment protocol. The adjuvant use of CHX showed a more expressive and significant improvement in clinical and microbiologic parameters, especially in the FMD protocol, followed by QS. |
metadata.dc.language: | Inglês |
metadata.dc.publisher.country: | Estados Unidos |
Publisher: | Wiley |
metadata.dc.rights: | Em verificação |
metadata.dc.identifier.doi: | 10.1902/jop.2015.150227 |
URI: | http://repositorio.unitau.br/jspui/handle/20.500.11874/2985 |
Issue Date: | 2015 |
Appears in Collections: | Artigos de Periódicos |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.